Biotech on the bounce in 3Q14

Boosted by a 10% gain in 3Q14, the BioCentury 100 Index recovered from the 22% correction earlier this year. Although industry financing was down on the previous four quarters (to $8.7 billion), initial public offerings (IPOs), follow-ons and private investments in public equity (PIPES) pulled in $4.5 billion last quarter, up 20% from 3Q13. More than $3 billion was raised via IPOs; private companies raised $1.8 billion.

Stock market performance

Global biotech initial public offerings

Global biotech venture capital investment

Global biotech industry financing

Notable 3Q14 deals

Box 1: Stock market performance

The BioCentury 100 was up 10% in 3Q14, whereas the NASDAQ Biotechnology Index was up 6%.

Box 2: Global biotech initial public offerings

30 IPOs pulled in $3 billion in 3Q14, more than twofold that raised by 17 companies in 3Q13.

Box 3: Global biotech venture capital investment

Private biotechs raised $1.8 billion in 3Q14, up 31% and down 35% from 3Q13 and 2Q14, respectively.

Box 4: Global biotech industry financing

Excluding partnerships, biotechs raised $8.7 billion in 3Q14, down 27% from $11.8 billion in the same period last year.

Box 5: Notable 3Q14 deals